Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Study demonstrates safety, preliminary efficacy of squalamine as 120-hour infusion

Jan. 9, 2002

Geron and Genetic Therapy enter licensing agreement to develop cancer therapy

Jan. 9, 2002

Telik updates progress of TLK-286

Jan. 9, 2002

MMP-2 inhibitors identified at Shionogi as anticancer agents

Jan. 8, 2002

NB-1011 enters phase I/II trial in colon cancer

Jan. 8, 2002

Abgenix initiates phase II trial of ABX-EGF in prostate cancer

Jan. 8, 2002

CDK inhibitors useful as anticancer agents reported by LG Chem

Jan. 7, 2002

Shire and HydroMed realign histrelin agreement

Jan. 7, 2002

Kyowa Hakko and Lilly report new potent antitumor compounds

Jan. 4, 2002

New dosage form of Atrix's Leuprogel licensed in by Sanofi-Synthelabo

Jan. 4, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...